Nadien AbouHashem1, Roan E Zaied2,3, Kholoud Al-Shafai4, Mariam Nofal5, Najeeb Syed6, Mashael Al-Shafai5. 1. Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, Doha, Qatar, nadine.ah@hotmail.com. 2. Liggins Institute, The University of Auckland, Auckland, New Zealand. 3. Institute of Infection, Immunity and Inflammation, MVLS, University of Glasgow, Glasgow, United Kingdom. 4. Sidra Research Department, Sidra Medicine, Doha, Qatar. 5. Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, Doha, Qatar. 6. Applied Bioinformatics Core, Sidra Medicine, Doha, Qatar.
Abstract
INTRODUCTION: Monogenic obesity (MO) is a rare genetic disease characterized by severe early-onset obesity in affected individuals. Previous genetic studies revealed 8 definitive genes for monogenic non-syndromic obesity; many were discovered in consanguineous populations. Here, we examined MO in the Qatari population, whose population is largely consanguineous (54%) and characterized by extensive obesity (45%). METHODS: Whole genome sequencing data of Qatar Biobank samples from 250 subjects with obesity and 250 subjects with normal weight, obtained in association with the Qatar Genome Programme, were searched for genetic variants in the genes known to be associated with MO (i.e., LEP, LEPR, POMC, PCSK1, MC3R, MC4R, MRAP2, and ADCY3). The impact of the variants identified was investigated utilizing in silico tools for prediction in combination with protein visualization by PyMOL. RESULTS: We identified potential MO variants in more than 5% of the cases in our cohort. We revealed 11 rare variants in 6 of the genes targeted, including two disease-causing variants in MC4R and MRAP2, all of which were heterozygous. Moreover, enrichment of a heterozygous ADCY3 variant (c.1658C>T; p.A553V) appeared to cause severe obesity in an autosomal dominant manner. CONCLUSION: These findings highlight the importance of implementing routine testing for genetic variants that predispose for MO in Qatar. Clearly, additional studies of this nature on populations not yet examined are required. At the same time, functional investigations, both in vitro and in vivo, are necessary in order to better understand the role of the variants identified in the pathogenesis of obesity.
INTRODUCTION: Monogenic obesity (MO) is a rare genetic disease characterized by severe early-onset obesity in affected individuals. Previous genetic studies revealed 8 definitive genes for monogenic non-syndromic obesity; many were discovered in consanguineous populations. Here, we examined MO in the Qatari population, whose population is largely consanguineous (54%) and characterized by extensive obesity (45%). METHODS: Whole genome sequencing data of Qatar Biobank samples from 250 subjects with obesity and 250 subjects with normal weight, obtained in association with the Qatar Genome Programme, were searched for genetic variants in the genes known to be associated with MO (i.e., LEP, LEPR, POMC, PCSK1, MC3R, MC4R, MRAP2, and ADCY3). The impact of the variants identified was investigated utilizing in silico tools for prediction in combination with protein visualization by PyMOL. RESULTS: We identified potential MO variants in more than 5% of the cases in our cohort. We revealed 11 rare variants in 6 of the genes targeted, including two disease-causing variants in MC4R and MRAP2, all of which were heterozygous. Moreover, enrichment of a heterozygous ADCY3 variant (c.1658C>T; p.A553V) appeared to cause severe obesity in an autosomal dominant manner. CONCLUSION: These findings highlight the importance of implementing routine testing for genetic variants that predispose for MO in Qatar. Clearly, additional studies of this nature on populations not yet examined are required. At the same time, functional investigations, both in vitro and in vivo, are necessary in order to better understand the role of the variants identified in the pathogenesis of obesity.
Authors: Doreen Zegers; Sigri Beckers; Fenna de Freitas; Armand V Peeters; Ilse L Mertens; Stijn L Verhulst; Raoul P Rooman; Jean-Pierre Timmermans; Kristine N Desager; Guy Massa; Luc F Van Gaal; Wim Van Hul Journal: Obesity (Silver Spring) Date: 2010-06-10 Impact factor: 5.002
Authors: Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo Journal: Genome Res Date: 2010-07-19 Impact factor: 9.043
Authors: Jing Yu; Luis E Gimenez; Ciria C Hernandez; Yiran Wu; Ariel H Wein; Gye Won Han; Kyle McClary; Sanraj R Mittal; Kylie Burdsall; Benjamin Stauch; Lijie Wu; Sophia N Stevens; Alys Peisley; Savannah Y Williams; Valerie Chen; Glenn L Millhauser; Suwen Zhao; Roger D Cone; Raymond C Stevens Journal: Science Date: 2020-04-24 Impact factor: 47.728
Authors: E Miraglia del Giudice; G Cirillo; N Santoro; L D'Urso; M T Carbone; R Di Toro; L Perrone Journal: Int J Obes Relat Metab Disord Date: 2001-01
Authors: B Paolini; P E Maltese; I Del Ciondolo; D Tavian; S Missaglia; C Ciuoli; M Zuntini; S Cecchin; M Bertelli; G Pompucci Journal: Genet Mol Res Date: 2016-08-19
Authors: Niels Grarup; Ida Moltke; Mette K Andersen; Maria Dalby; Kristoffer Vitting-Seerup; Timo Kern; Yuvaraj Mahendran; Emil Jørsboe; Christina V L Larsen; Inger K Dahl-Petersen; Arthur Gilly; Daniel Suveges; George Dedoussis; Eleftheria Zeggini; Oluf Pedersen; Robin Andersson; Peter Bjerregaard; Marit E Jørgensen; Anders Albrechtsen; Torben Hansen Journal: Nat Genet Date: 2018-01-08 Impact factor: 38.330